Company Overview


Message from the President

As the world’s leading country in terms of longevity, Japan is set to become a super-aged society. In this age, life can be extended through self-care. As a way of promoting self-care in Japan, a tax reduction system for switching to OTC drugs will take effect from 2017. However, the market structure is on the verge of changing significantly due to population decline brought about by the low birth rate, as well as the penetration of e-commerce.

In Sato Pharmaceutical’s core business area, consumer healthcare, we drive the development of advanced, highly-value-added products. At the same time, to create an environment in which consumers can effectively use OTC pharmaceutical products, we are actively engaged in supporting stores’ efforts to function as health consultation centers.

In our ethical pharmaceutical business, we are expanding the brand by developing specialized products for the field of dermatology. To meet the needs of a wide range of medical practices, we are strengthening the system of new drug development and research by joining hands with domestic and international companies and research institutions.

Internationally, we are committed to the promotion and popularization of the Sato brand by focusing on the Asian region and using our seven business centers spread across North America and Europe.

To fulfill our responsibility of providing a secure supply of high-quality products, we have continued to expand our international and domestic production network and distribution centers to create an efficient supply chain. We are doing all we can to reduce the environmental impact of our production system.

Sato Pharmaceuticals celebrated its 100th anniversary in 2015. Based on our corporate philosophy of Healthcare Innovation, we will work to contribute to consumers’ health by providing products such as OTC and ethical pharmaceuticals.

I want to thank you, and I ask for your continued advice and support.

Seiichi Sato
President and CEO